Aegerion Pharmaceuticals, Inc. Receives European Approval for LOJUXTA™ (lomitapide) to Treat Homozygous Familial Hypercholesterolemia (HoFH)

Published: Aug 01, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has approved LOJUXTA™ (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH).

Help employers find you! Check out all the jobs and post your resume.

Back to news